A second patient died in a late-stage trial of Zafgen's experimental obesity treatment, highlighting safety concerns associated with drugs that aim to treat a condition that affects one in three Americans.
The company said a patient receiving its drug, beloranib, died from a blockage in an artery in the lung.
Obesity treatments have been plagued by safety concerns, particularly related to heart risk, increased suicidal thoughts and birth defects, and several have been taken off the market.
The U.S. Food and Drugs Administration (FDA) has approved drugs made by Vivus, Orexigen Therapeutics and Arena Pharmaceuticals, but has asked for additional studies to check for safety of these drugs.
The treatments suppress appetite by tinkering with nerve signals, telling the brain that the stomach is full.
The company said a patient receiving its drug, beloranib, died from a blockage in an artery in the lung.
Obesity treatments have been plagued by safety concerns, particularly related to heart risk, increased suicidal thoughts and birth defects, and several have been taken off the market.
The U.S. Food and Drugs Administration (FDA) has approved drugs made by Vivus, Orexigen Therapeutics and Arena Pharmaceuticals, but has asked for additional studies to check for safety of these drugs.
The treatments suppress appetite by tinkering with nerve signals, telling the brain that the stomach is full.
No comments:
Post a Comment